Amneal Pharmaceuticals公司近日披露了其药物Crexont®针对帕金森病治疗的第四阶段Elevate-Pd研究的补充积极中期数据。最新结果显示，当患者从现有治疗药物Rytary®转用Crexont®后，每日能够获得超过3小时的额外"良好状态"时间。这一数据进一步验证了Crexont®在改善帕金森病患者日常生活质量方面的显著疗效。
Amneal Pharmaceuticals公司近日披露了其药物Crexont®针对帕金森病治疗的第四阶段Elevate-Pd研究的补充积极中期数据。最新结果显示，当患者从现有治疗药物Rytary®转用Crexont®后，每日能够获得超过3小时的额外"良好状态"时间。这一数据进一步验证了Crexont®在改善帕金森病患者日常生活质量方面的显著疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.